Source: Eur Respir J 2016; 47: 1208-1218
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Galanis Ilias, Lindstrand Ann, Darenberg Jessica, Browall Sarah, Nannapaneni Priyanka, Sjöström Karin, Morfeldt Eva, Naucler Pontus, Blennow Margareta, Örtqvist Åke, Henriques-Normark Birgitta. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J 2016; 47: 1208-1218

Member's Comments

No comment yet.

Related content which might interest you: Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013) Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014 The remaining challenges of pneumococcal disease in adults Source: Eur Respir Rev 2012; 21: 57-65 Year: 2012 Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma Year: 2013 Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia Source: Eur Respir J 2015; 45: 1632-1641 Year: 2015 Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands Source: Eur Respir J 2015; 46: 1407-1416 Year: 2015 Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population Source: Eur Respir J 2016; 48: 1492-1496 Year: 2016 Use of the pneumococcal 23-valent polysaccharide vaccine in recruits in Russia Source: Eur Respir J 2004; 24: Suppl. 48, 363s Year: 2004 Invasive pneumococcal disease (IPN) and pneumococcal vaccination in our setting Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany Source: Eur Respir J, 59 (2) 2102432; 10.1183/13993003.02432-2021 Year: 2022 Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine Source: Eur Respir J 2013; 42: 1595-1603 Year: 2013 Dynamics of serotypic composition of nasopharyngeal pneumococcal isolates in children pneumococcal nasopharyngeal colonization after the introduction of the vaccination program in Moscow Source: Virtual Congress 2020 – Different aspects of paediatric viral and bacterial lung infections Year: 2020 Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types Source: Eur Respir J 2014; 44: 1646-1657 Year: 2014 Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough. Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function Year: 2021 Compliance with the pneumococcal and influenza vaccination recommendations in patients with COPD in Catalonia (Spain) Source: Eur Respir J 2005; 26: Suppl. 49, 594s Year: 2005 Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects Source: Eur Respir J 2005; 26: 1086-1091 Year: 2005 Clinical evolution of patients with COPD after administration of 23-valent pneumococcal capsular polysacharide vaccine (PCPV) Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005 Serotype dynamics in pneumococcal diseases and the performance of vaccination strategies for older adults in germany Source: Virtual Congress 2020 – How do different treatment strategies translate into costs Year: 2020